Effects of Vitamin D Supplementation on Strength, Bone Density, and Injury Risk in Collegiate Athletes

NCT ID: NCT03151174

Last Updated: 2024-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-29

Study Completion Date

2018-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine whether Vitamin D supplementation improves strength and bone density, and reduces the risk of injury in collegiate athletes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vitamin D is a hormone that is important for bone and muscle health. As such, not having enough vitamin D in your body is associated with increased risk of injury and reduced health and athletic performance. It is often recommended that individuals who have low levels of vitamin D take vitamin D supplements. However, the effects of vitamin D supplementation on health and strength gains in collegiate athletes are not known. The goal of this study is to determine whether vitamin D supplementation increases strength and bone density, while reducing the risk of injury in collegiate athletes. Fasting vitamin D concentrations will be measured and athletes will be supplemented daily with Vitamin D for 8-12 weeks. The amount of supplementation will depend on whether the athlete is categorized as sufficient (\>30ng/ml), insufficient (20-35ng/ml), or deficient (\<20ng/ml). Vitamin D concentrations, strength, bone density, and injury risk will be assessed before and after the intervention period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Subjects will either receive placebo, 5000IU, or 10000IU per day of Vitamin D for 8-12 weeks.
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Any individuals involved in study measures will also be masked.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D - 10000IU

These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.

Group Type EXPERIMENTAL

Vitamin D 10000 UNT

Intervention Type DRUG

10000 IU Vitamin D per day

Vitamin D - 5000IU

These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.

Group Type EXPERIMENTAL

Vitamin D 5000 UNT

Intervention Type DRUG

5000 IU Vitamin D per day

Placebo

These individuals have been categorized as Vitamin D sufficient and will receive placebo.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D 10000 UNT

10000 IU Vitamin D per day

Intervention Type DRUG

Vitamin D 5000 UNT

5000 IU Vitamin D per day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* athlete for a sanctioned Virginia Tech sport

Exclusion Criteria

* pregnant or trying to become pregnant, currently taking vitamin D (\>600IU/day), calcium (\>1000mg/dl), taking any performance enhancing supplements (example, creatine), or any other medication or nutritional supplements that might influence the study variables, cardiac or thyroid problems, have diabetes, or epilepsy
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Virginia Polytechnic Institute and State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matthew Hulver, PhD

Role: PRINCIPAL_INVESTIGATOR

Virginia Polytechnic Institute and State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Virginia Tech

Blacksburg, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

25-Hydroxyvitamin D Pharmacokinetic Study
NCT03401541 COMPLETED EARLY_PHASE1
Treatment of Vitamin D Insufficiency
NCT00933244 COMPLETED PHASE4
Effect of Vitamin D Treatment on Fatigue
NCT02022475 COMPLETED PHASE3
The D-BIICEP Study
NCT03253055 COMPLETED